Abstract:Polysaccharide-based vaccines cannot stimulate long-lasting immune response in infants due to their inability to elicit a T-cell-dependent immune response. This has been addressed using conjugation technology, where conjugates were produced by coupling a carrier protein to polysaccharides using different conjugation chemistries, such as cyanylation, reductive amination, ethylene diamine reaction, and others. Many glycoconjugate vaccines that are manufactured using different conjugation technologies are already in the market for neonates, infants and young children (e.g., Haemophilus influenzae type-b, Streptococcus pneumoniae and Neisseria meningitidis vaccines), and all of them elicit a T-cell dependent immune response. To manufacture glycoconjugate vaccines, the capsular polysaccharide is first activated by converting its hydroxyl groups to aldehyde-, cyanyl-, or cyanate ester groups, depending on the conjugation chemistry selected. The oxidized and reduced aldehyde functional groups of the polysaccharides are subsequently reacted with the amino groups of carrier protein by reductive amination to form a stable amide bond. In CDAP-based conjugation, the polysaccharide -OH groups are activated to form cyanyl-, or cyanate ester groups to react with the amino groups of carrier protein and forms an isourea bond. Understanding the extent of polysaccharide activation/modification is essential since it directly influences the molar mass of the conjugate, its stability, and the immunogenicity of the product. Reported methods are available to estimate the aldehyde groups of polysaccharides generated by reductive amination. However, no method is available to quantify the cyanyl or cyanate ester (-OCN) groups generated by cyanylation with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP). We report a novel strategy using an O-phthalaldehyde (OPA) derivatization process followed by size-exclusion chromatography (SEC) high-performance liquid chromatography (HPLC) separation and UV detection. The cyanate ester groups on the activated polysaccharide directly reveal the extent of polysaccharide activation/modification and the residual activated groups in the purified conjugates. This method would be useful for conjugate vaccine manufacturing using CDAP chemistry.

Research on Degradation of Type 9Ⅴ Pneumococcal Capsular Polysaccharide

Studies on Vaccine Control and Immunogenicity of Polysaccharides of Streptococcus pneumoniae

Simplified Process for Preparing Native and Depolymerized Capsular Polysaccharides of Streptococcus Pneumoniae

Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System

Partial depolymerization of capsular polysaccharides isolated from Streptococcus pneumoniae serotype 2 by various methods

Novel manufacturing process of pneumococcal capsular polysaccharides using advanced sterilization methods

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D of Streptococcus pneumoniae with Their Immunological Studies

The experimental research of tne preparation for pneumococcal conjugate vaccine using pneumolysin as a protein carrier and its immumogenicity in mice

Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines

Simultaneous purification and depolymerization of Streptococcus pneumoniae serotype 2 capsular polysaccharides by trifluoroacetic acid

Characterization of pneumococcal serotype 7F in vaccine conjugation

Development of Klebsiella pneumoniae Capsule Polysaccharide-Conjugated Vaccine Candidates Using Phage Depolymerases

Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence

Synthesis and immunological study of tetrasaccharide repeating units of capsular polysaccharide of Group B Streptococcus serotype VIII and their protein conjugates

Conjugate of Structurally Reassigned Pneumococcal Serotype 31 Polysaccharide with CRM197 Elicited Potent Immune Response

Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8‐fusion protein (Hla‐MntC‐SACOL0723) immunoconjugates

O-phthalaldehyde based quantification of polysaccharide modification in conjugate vaccines

Effect of O‐acetylation on the antigenicity and glycoconjugate immunogenicity of the Streptococcus pneumoniae serotype 7F capsular polysaccharide

Quantitative determination of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharides by enzyme-linked immunosorbent assay

Decoding capsule synthesis in Streptococcus pneumoniae